Vesicular Monoamine Transporter Type 2 Inhibition Can Lead to Effective and Tolerable Management of Tardive Dyskinesia

Authors

Leslie L. Citrome, New York Medical CollegeFollow

Journal Title

Evidence Based Mental Health

First Page

e12

Document Type

Article

Publication Date

August 2018

Department

Psychiatry and Behavioral Sciences

Recommended Citation

Citrome, L. L. (2018). Vesicular Monoamine Transporter Type 2 Inhibition Can Lead to Effective and Tolerable Management of Tardive Dyskinesia. Evidence Based Mental Health, 21 (3), e12. https://doi.org/10.1136/eb-2017-102825